Literature DB >> 2777445

Plasminogen activators and antiplasmin activity in atopic dermatitis.

T Lotti1, M L Battini, L Brunetti, P Fabbri, E Panconesi.   

Abstract

Cutaneous deposits of fibrinogen activity in lesional skin, plasmatic fibrinolytic activity, and antiplasmin activity (alpha 2 macroglobulin, alpha 1 antitrypsin and antithrombin III) were evaluated in a group of ten patients with atopic dermatitis and in a sex- and age-matched control group. Plasma fibrinolytic activity was increased in the acute phase of the disease (p less than 0.05). The levels of circulating antiplasmins appeared similar in the patients and the control group. Cutaneous fibrinolytic activity was increased in the acute phase of the disease in 5 of 5 cases, suggesting a role of the fibrinolytic system in the amplification of the inflammatory phenomenon in that phase of the disease. In the chronic lichenified phase, CFA was decreased in 3 of 5 cases leading to an excessive deposit of fibrin in the skin. This could be correlated with the abnormal vascular response (blanching phenomenon). On the basis of these data, the therapeutic use of the antifibrinolytic agents only seems rational in the acute phase of the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777445     DOI: 10.1111/j.1365-4362.1989.tb02506.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

2.  Blood serum metabolome of atopic dermatitis: Altered energy cycle and the markers of systemic inflammation.

Authors:  Aigar Ottas; Dmytro Fishman; Tiia-Linda Okas; Tõnu Püssa; Peeter Toomik; Aare Märtson; Külli Kingo; Ursel Soomets
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.